From: The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review
Study | Liver function improvement | Histology alleviation |
---|---|---|
Monotherapy | ||
Laurin et al. [24]* | ALT (−30%), ALP (−8%) and γGT (−45%) | steatosis improved |
Lindor et al. [25] | ALT in −31% vs. −29% | steatosis in −18% vs. −14%; inflammation in −0 vs. −0.1, fibrosis in 0 vs. 0 |
Dufour et al. [20] | ALT in −36% vs. −2% | steatosis in −13% vs. −14%, inflammation in −0.8 vs. −0.02, fibrosis in +0.3 vs. +0.4 |
Kiyici et al. [26] | ALT in −26% vs. −40% ALT in 76.0 vs. 55.1, γGT in 47.8vs 32.2 | liver density +20% vs. +35% (in UDCA group between after and before therapy) |
Hong Qian, et al. [32] | Effective ratio24/26 vs. 23/27 | not mentioned |
Zhu Hong-juan [27] | liver function and symptom in 25/30 vs. 15/30 | not mentioned |
Ratziu et al. [28] | ALT in −28% vs. −2% γGT in −51% vs. +19% | fibrosis in −11% vs. +10%# |
Leuschner et al. [29] | ALT in −41% vs. −35% | Brunt score in −14% vs. −14% NAS activity score in −21% vs. −18% |
UDCA combined with other drugs | ||
Dufour et al. [20] | ALT in −42% vs. −2% AST in −30% vs. +6% | steatosis in −1.4 vs. −0.5; inflammation in −2.2 vs. −0.8 |
Zhuang Xue-shan [30] | Effective rate 36/40 vs. 29/42 | 26/40 vs. 17/42 in steatosis (ultrasound) |
Sun Yan [31] | ALT in −79 vs. −72, AST in −31 vs. −8, Effective rate 65/76 vs. 37/61 | not mentioned |
Lv Hong [33] | ALT in −45.9 vs. −16.1 AST in −40.1 vs. −29.5 | no report in histology |
Liu Zhi-ye [34] | Effective rate 86/96 vs. 38/54 | no report in histology |